drugset / Trial / NCT05816382
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
NaSingle-groupOpen-labelTreatment
Summary
The main aim is to evaluate the safety and tolerability of TAK-861 in participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.
Timeline
- Start
- 2023-04-05
- Primary completion
- 2028-02-28
- Completion
- 2028-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | oveporexton | Small molecule | — | — |